Eylea HD Launched By Regeneron As Linvoseltamab Faces Production Hurdles
Regeneron's Eylea HD Q2 sales hit $304M, with total franchise sales at $1.53B, despite Vabysmo competition.
Breaking News
Aug 02, 2024
Mrudula Kulkarni

During the second quarter, Regeneron’s high-dose Eylea
achieved U.S. sales of $304 million, falling slightly short of analyst
expectations but marking a notable increase from the $200 million recorded in
the first quarter. This launch has revitalized the Eylea franchise, which had
experienced declining U.S. sales for three consecutive quarters due to
competition from Roche’s Vabysmo. Regeneron also announced a likely delay in
the FDA decision on its multiple myeloma therapy linvoseltamab, initially set for
August 22, due to a manufacturing issue.
Overall, Eylea's franchise sales reached $1.53 billion in
the second quarter, showing a 2% year-over-year increase and a 9% sequential
rise, the highest since the third quarter of 2022 when U.S. sales peaked at
$1.63 billion. Eylea HD, now in its third full quarter, offers a longer
duration of effect (four months) compared to the original version (two months).
In comparison, Roche’s Vabysmo, launched in early 2022 as a longer-lasting
alternative to Eylea, reported global sales of 309 million Swiss francs ($324
million) in its third full quarter.
Len Schleifer, Regeneron CEO said that Eylea HD “continues
to out-perform recent launches in the anti-VEGF category. We are encouraged
that despite increased competition in the anti-VEGF space, we have achieved a
strong Eylea HD launch trajectory while maintaining our category-leading
combined Eylea HD and Eylea market share of 45%.”
Roche recently announced that Vabysmo's global sales hit 947
million Swiss francs ($1.1 billion) last quarter, surpassing the blockbuster
threshold for the first time. Bayer, responsible for Eylea's international
market, is scheduled to release its quarterly earnings next week.nEylea’s
strong performance enabled Regeneron to surpass revenue expectations by nearly
$200 million, with quarterly revenue reaching $3.55 billion, reflecting a 12%
year-over-year increase and a 13% sequential rise.
Dupixent played a crucial role, generating $3.56 billion in
global sales. Sanofi records revenues for Dupixent under their antibody
partnership with Regeneron, which reported $1.1 billion in collaboration
revenue for the quarter, marking a 21% year-over-year increase. Regeneron is
poised for further growth from Dupixent with a potential FDA approval for
chronic obstructive pulmonary disorder (COPD) expected in September.
Additionally, sales of Libtayo surged by 42% to $297 million, positioning the
cancer drug, approved in 2018, to achieve blockbuster status this year.